CPH:GMAB

Genmab Stock

DENMARK |CO |DKK

Price
kr2,700.00
Change
1.43%
Today's Range
kr2,675.00 - kr2,720.00
52-Week Range
kr1,901.50 - kr3,100.00
Market Cap
kr176.53B
Volume
238.42K

About Genmab (CPH:GMAB)

(CPH:GMAB) Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Show more

GMAB Stock Price

Statistics Highlights (CPH:GMAB)

Shares Outstanding 65.38M Beta 0.60
Public Float 64.61M P/E Ratio 70.95
% Short of Float - Dividend (Yield) -
Held by Insiders 4.63% Ex-Dividend Date
Held by Institutions 49.30% IPO Date -

GMAB Financial Summary

|
Dec 20 Dec 19 Dec 18
Revenue kr10.11B kr5.37B kr3.03B
EBITDA kr6.17B kr3.01B kr1.70B
Net Income kr4.76B kr2.17B kr1.47B
Total Assets kr21.14B kr15.14B kr8.46B
Total Cash kr7.26B kr3.55B kr532.91M
Total Debt kr kr kr
Jun 21 Mar 21 Dec 20
Revenue kr1.97B kr1.58B kr2.04B
EBITDA kr852.00M kr1.43B kr-128.00M
Net Income kr306.00M kr1.10B kr581.00M
Total Assets kr22.48B kr22.21B kr21.14B
Total Cash kr9.48B kr7.89B kr7.26B
Total Debt kr kr kr

GMAB Stock Price History

Genmab Annual Stock Price History

Year Open Close Change
2021 kr2405.00 kr2700.00 12.27%
2020 kr1483.50 kr2405.00 62.12%

Genmab Daily Stock Price History

Date Open High Low Close Change Volume
Sep 17, 2021 kr2682.00 kr2720.00 kr2675.00 kr2700.00 1.43% 238.42K
Sep 16, 2021 kr2690.00 kr2694.00 kr2648.00 kr2662.00 -1.48% 153.57K

(CPH:GMAB) Stock Price FAQs

What is today's stock price of Genmab (CPH:GMAB)?

  • The current stock price of Genmab (CPH:GMAB) is kr2700.00.
  • Today GMAB stock price opened at kr2682.00 after previous close of kr2662.00.
  • During the day, Genmab stock quote has varied from a low of kr2675.00 to a high of kr2720.00.

What is Genmab's 52-week change?

  • GMAB 52-week high stock quote is kr3100.00, which is 14.80% above the current share price.
  • The Genmab (CPH:GMAB) 52-week low stock price is kr1901.50, which is 29.60% below the current share price.
  • Genmab share price volatility (52-week beta) is 0.60.

Genmab (CPH:GMAB) FAQ

How Much is Genmab Worth?

Genmab's worth today based on market capitalisation is kr176.53B

How much money does Genmab make?

Last quarter (ended on June 30 ,2021) Genmab generated a net income of kr306.00M, representing a 1003.92% increase compared to the same quarter a year before (ended on June 30 ,2020).
Last fiscal year (ended on December 31 ,2020) Genmab generated a net income of kr4.76B, representing a 119.67% increase compare to the previous fiscal year (ended on December 31 ,2019).
View More Details on Genmab's “Financials” Section

How much dividend does Genmab Pay?

The current annualized dividend payout for GMAB stock is kr0.00, the dividend yield is 0.00% and the payout ratio is 0.00%.
View More Details on Genmab's "Dividend" Section

What were Genmab’s last Earnings results?

For the last quarterly earnings period (ended on June 30, 2021) GMAB reported kr0.74 EPS for the quarter, beating the average analysts’ forecasts of kr0.67 EPS by kr0.07 (10.45%).
View More Details on Genmab's 'Earnings' Section

When is the next earnings date for Genmab (CPH:GMAB)?

Genmab is expected to report earnings on November 03 ,2021.
View More Details on Genmab's 'Earnings' Section

What is Genmab’s Price to Earning (PE) ratio?

Genmab has a Price to Earning (P/E) ratio of 70.95. GMAB stock also has a Price to Sales (P/S) ratio of 24.11, a Price to Book of 8.72 and Price/Earnings to Growth (PEG) of 6.48.

What is the Genmab's ticker?

Genmab trades on the Copenhagen stock market in Denmark under the ticker symbol "GMAB". Genmab’s stock symbol can also be displayed as "CPH:GMAB".

Who are the owners of Genmab?

Genmab (CPH:GMAB) is owned by 49.30% institutional shareholders and by 4.62% insiders. The rest is owned by the public.
Explore More Details on Genmab's “Ownership” Section

Who are the key executives of Genmab (GMAB)?

Genmab's key executive team includes the following managers:

  • Dr. Jan G.J. van de Winkel, Co-Founder, Pres & CEO (1961)
  • Mr. Anthony Pagano, Exec. VP & CFO (1978)
  • Mr. Anthony Mancini, Exec. VP & COO (1971)
  • Mr. Peter Storm Kristensen, Director of Legal Lead Corp. & Non-Independent Director (1975)
  • Dr. Judith V. Klimovsky, Exec. VP & Chief Devel. Officer (1958)
  • Dr. Mijke Zachariasse Ph.D., Director of Protein Production & Chemist and Non-Independent Director (1974)
  • Dr. Rima Bawarshi Nassar Ph.D., VP, Head of Global Regulatory Affairs ? Oncology & Non-Independent Director (1953)
  • Mr. Peter Ros, Sr. Director of Fin. & Accounting (NA)
  • Mr. Andrew Carlsen, Sr. Director & Head of Investor Relations (NA)
  • Ms. Birgitte Stephensen M.Sc., Sr. VP & Head of Global IPR and Legal (1961)

What is Genmab’s Sector & Industry Classification?

Genmab (CPH:GMAB) is classified under the "Healthcare" sector and under the "Biotechnology" industry.

What is the ESG rating for Genmab (CPH:GMAB) ?

ESG scores assess the degree to which a company’s enterprise business value is at risk driven by environmental, social, and governance issues. The scores are a measure of risk on an absolute scale of 0-100, with a lower score meaning less risk.

GMAB’s total ESG score is 34.80. The company’s environmental score is 7.63, social score is 26.40 and governance score is 13.27.
Genmab (CPH:GMAB) is involved in the following activities (which decreases its ESG score) : "animalTesting".

How many employees work for Genmab?

Currently the number of employees working for Genmab is 1,029.

Where are Genmab's Headquarters?

Genmab (CPH:GMAB) is headquartered in Denmark.

What are Genmab's Address and Phone Number?

Genmab’s mailing address is Kalvebod Brygge 43, Copenhagen, Denmark, 1560.
The company’s phone number is 45 70 20 27 28.

What is the official website for Genmab?

Genmab’s official website is http://www.genmab.com